Moleculin Gains Japanese Patent Allowance for Annamycin

Moleculin Biotech ( (MBRX) ) has issued an update.

On February 17, 2026, Moleculin Biotech, Inc. announced that the Japan Patent Office issued a notice of allowance for a patent application covering methods of reconstituting and preparing liposomal Annamycin for intravenous use. The allowed claims focus on controlled temperature conditions to ensure consistent dosing, stability and handling, extending existing U.S. and European protection for the company’s lead anthracycline candidate.

The Japanese allowance bolsters Moleculin’s international intellectual property position as it advances Annamycin, which has Fast Track and multiple Orphan Drug Designations, through pivotal Phase 3 development in relapsed or refractory acute myeloid leukemia. The added patent coverage in a major market underpins the long-term commercial potential of the therapy and supports Moleculin’s strategy to secure regulatory approvals and future commercialization across key global territories.

The most recent analyst rating on (MBRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and prior negative equity) and bearish technicals (below key moving averages with negative MACD). Positive corporate developments (clinical progress and regained Nasdaq compliance) provide some offset, while valuation is limited by ongoing losses and no dividend.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on therapies for hard-to-treat tumors and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline being developed for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, alongside additional oncology and antiviral programs including WP1066 and WP1122.

The company is running the pivotal MIRACLE Phase 3 trial of Annamycin in combination with cytarabine for relapsed or refractory AML, following a completed Phase 1B/2 study. Annamycin holds Fast Track and multiple Orphan Drug Designations from U.S. and European regulators, reflecting its potential as a non-cardiotoxic alternative to existing anthracyclines in key hematologic and solid tumor indications.

Average Trading Volume: 287,684

Technical Sentiment Signal: Sell

Current Market Cap: $13.36M

See more insights into MBRX stock on TipRanks’ Stock Analysis page.